ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma†,‡

被引:36
|
作者
Rodolakis, Alexandros [1 ]
Scambia, Giovanni [2 ]
Planchamp, Francois [3 ]
Acien, Maribel [4 ]
Sardo, Attilio Di Spiezio [5 ]
Farrugia, Martin [6 ]
Grynberg, Michael [7 ,8 ,9 ]
Pakiz, Maja [10 ]
Pavlakis, Kitty [11 ,12 ]
Vermeulen, Nathalie [13 ]
Zannoni, Gianfranco [14 ]
Zapardiel, Ignacio [15 ]
Macklon, Kirsten Louise Tryde [16 ]
机构
[1] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Unit Gynaecol Oncol, Sch Hlth Sci, Athens 11528, Greece
[2] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[3] Inst Bergonie, Clin Res Unit, Bordeaux, France
[4] Miguel Hernandez Univ, San Juan Univ Hosp, Obstet & Gynecol Dept, Alicante, Spain
[5] Univ Naples Federico II, Sch Med, Dept Publ Hlth, Gynecol & Obstet Unit, Naples, Campania, Italy
[6] Spencer Private Hosp, East Kent, England
[7] Hop Antoine Beclere, AP HP, Dept Reprod Med & Fertil Preservat, Clamart, France
[8] Hop Jean Verdier, AP HP, Dept Reprod Med & Fertil Preservat, Bondy, France
[9] Univ Paris Saclay, St Aubin, France
[10] Univ Med Ctr, Dept Gynecol & Breast Oncol, Maribor, Slovenia
[11] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Pathol Dept 1, Sch Hlth Sci, Athens, Slovenia
[12] IASO Womens Hosp, Pathol Dept, Athens, Greece
[13] European Soc Human Reprod & Embryol, Strombeek Bever, Belgium
[14] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Pathol, Dipartimento Sci Salute Donna & Bambino & Sanita, Rome, Italy
[15] La Paz Univ Hosp, Dept Gynecol Oncol, Madrid, Spain
[16] Copenhagen Univ Hosp, Fertil Dept, Copenhagen, Denmark
关键词
uterine cancer; guideline; fertility preservation; endometrial carcinoma; oncofertility; DEEP MYOMETRIAL INVASION; COMPLEX ATYPICAL HYPERPLASIA; DETECTING CERVICAL INVASION; POLYCYSTIC-OVARY-SYNDROME; YOUNG-WOMEN; TRANSVAGINAL ULTRASOUND; DIAGNOSTIC-ACCURACY; ESGO/ESTRO/ESP GUIDELINES; PREOPERATIVE ASSESSMENT; REPRODUCTIVE OUTCOMES;
D O I
10.1093/hropen/hoac057
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
STUDY QUESTION How should fertility-sparing treatment of patients with endometrial carcinoma be performed? SUMMARY ANSWER Forty-eight recommendations were formulated on fertility-sparing treatment of patients with endometrial carcinoma. WHAT IS KNOWN ALREADY The standard surgical treatment of endometrial carcinoma consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in endometrial carcinoma in a multidisciplinary setting. While addressing also work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility-sparing treatment. STUDY DESIGN, SIZE, DURATION A collaboration was set up between the ESGO, the European Society of Human Reproduction and Embryology (ESHRE) and the European Society for Gynaecological Endoscopy (ESGE), aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. PARTICIPANTS/MATERIALS, SETTING, METHODS ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practising clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgement was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives. MAIN RESULTS AND THE ROLE OF CHANCE The multidisciplinary development group formulated 48 recommendations in four sections; patient selection, tumour clinicopathological characteristics, treatment and special issues. LIMITATIONS, REASONS FOR CAUTION Of the 48 recommendations, none could be based on level I evidence and only 16 could be based on level II evidence, implicating that 66% of the recommendations are supported only by observational data, professional experience and consensus of the development group. WIDER IMPLICATIONS OF THE FINDINGS These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario. STUDY FUNDING/COMPETING INTEREST(S) All costs relating to the development process were covered from ESGO, ESHRE and ESGE funds. There was no external funding of the development process or manuscript production. G.S. has reported grants from MSD Italia S.r.l., advisory boards for Storz, Bayer, Astrazeneca, Metronic, TESARO Bio Italy S.r. l and Johnson & Johnson, and honoraria for lectures from Clovis Oncology Italy S.r.l. M.G. has reported advisory boards for Gedeon Richter and Merck. The other authors have reported no conflicts of interest. DISCLAIMER This document represents the views of ESHRE, ESGO and ESGE which are the result of consensus between the relevant stakeholders and where relevant based on the scientific evidence available at the time of preparation. The recommendations should be used for informational and educational purposes. They should not be interpreted as setting a standard of care, or be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, nor variations based on locality and facility type.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma
    Rodolakis, Alexandros
    Scambia, Giovanni
    Planchamp, Francois
    Acien, Maribel
    Sardo, Attilio Di Spiezio
    Farrugia, Martin
    Grynberg, Michael
    Pakiz, Maja
    Pavlakis, Kitty
    Vermeulen, Nathalie
    Zannoni, Gianfranco
    Zapardiel, Ignacio
    Macklon, Kirsten Louise Tryde
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (02) : 208 - 222
  • [2] ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma
    Rodolakis, A.
    Scambia, G.
    Planchamp, F.
    Acien, M.
    Sardo, A. Di Spiezio
    Farrugia, M.
    Grenberg, M.
    Pakiz, M.
    Pavlakis, K.
    Vermeulen, N.
    Zannoni, G.
    Zapardiel, I.
    Macklon, K. L. Tryde
    FACTS VIEWS AND VISION IN OBGYN, 2023, 15 (01): : 3 - 23
  • [3] Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE
    Morice, Philippe
    Scambia, Giovanni
    Abu-Rustum, Nadeem R.
    Acien, Maribel
    Arena, Alessandro
    Brucker, Sara
    Cheong, Ying
    Collinet, Pierre
    Fanfani, Francesco
    Filippi, Francesca
    Eriksson, Ane Gerda Zahl
    Gouy, Sebastien
    Harter, Philipp
    Matias-Guiu, Xavier
    Pados, George
    Pakiz, Maja
    Querleu, Denis
    Rodolakis, Alexandros
    Rousset-Jablonski, Christine
    Stepanyan, Artem
    Testa, Antonia Carla
    Macklon, Kirsten Tryde
    Tsolakidis, Dimitrios
    De Vos, Michel
    Planchamp, Francois
    Grynberg, Michael
    LANCET ONCOLOGY, 2024, 25 (11): : e602 - e610
  • [4] Fertility-sparing treatment for patients with endometrial carcinoma
    Ind, T.
    FACTS VIEWS AND VISION IN OBGYN, 2023, 15 (01): : 1 - 2
  • [5] A practical guideline on the fertility-sparing treatment of patients with endometrial carcinoma and atypical endometrial hyperplasia
    Catena, Ursula
    Macklon, Kirsten Louise Tryde
    Rodolakis, Alexandros
    Scambia, Giovanni
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2025,
  • [6] Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma
    Fujiwara, Hiroyuki
    Jobo, Toshiko
    Takei, Yuji
    Saga, Yasushi
    Imai, Manami
    Arai, Tsutomu
    Taneichi, Akiyo
    Machida, Shizuo
    Takahashi, Yoshifumi
    Suzuki, Mitsuaki
    ONCOLOGY LETTERS, 2012, 3 (05) : 1002 - 1006
  • [7] Molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia
    Martin, Tiermes Marina
    Matas, Isabel
    Munmany, Meritxell
    Celada, Cristina
    Diaz-Feijoo, Berta
    Glickman, Ariel
    Carreras, Nuria
    Fuste, Pere
    Torne, Aureli
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A245 - A246
  • [8] Fertility-sparing treatment in women with endometrial cancer
    Won, Seyeon
    Kim, Mi Kyoung
    Seong, Seok Ju
    CLINICAL AND EXPERIMENTAL REPRODUCTIVE MEDICINE-CERM, 2020, 47 (04): : 237 - 244
  • [9] Radiomics-based fertility-sparing treatment in endometrial carcinoma: a review
    Wang, Yuanjian
    Chen, Zhongshao
    Liu, Chang
    Chu, Ran
    Li, Xiao
    Li, Mingbao
    Yu, Dexin
    Qiao, Xu
    Kong, Beihua
    Song, Kun
    INSIGHTS INTO IMAGING, 2023, 14 (01)
  • [10] Radiomics-based fertility-sparing treatment in endometrial carcinoma: a review
    Yuanjian Wang
    Zhongshao Chen
    Chang Liu
    Ran Chu
    Xiao Li
    Mingbao Li
    Dexin Yu
    Xu Qiao
    Beihua Kong
    Kun Song
    Insights into Imaging, 14